« Back to Medicines list

Genticin 80 mg/2 ml Solution for Injection

  • Name:

    Genticin 80 mg/2 ml Solution for Injection

  • Company:
    info
  • Active Ingredients:

    Gentamicin sulfate

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Summary of Product Characteristics last updated on medicines.ie: 14/3/2017
print

Print ViewKeyword Search SPC

ADVANZ Pharma

advanz-full-rgb_1543842253

Company Products

Medicine NameActive Ingredients
Medicine Name Celevac 500 mg tablets Active Ingredients Methylcellulose
Medicine Name Chloromycetin 0.5% w/v Redidrops Eye Drops, Solution. Active Ingredients Chloramphenicol
Medicine Name Clarithromycin 500 mg, Powder for Concentrate for Solution for Infusion Active Ingredients Clarithromycin lactobionate
Medicine Name Codipar 15mg/500mg Capsules Active Ingredients Codeine Phosphate, Paracetamol
Medicine Name Codipar 15mg/500mg Capsules Active Ingredients Codeine Phosphate Hemihydrate, Paracetamol
Medicine Name Codipar 15mg/500mg Effervescent Tablets Active Ingredients Codeine Phosphate Hemihydrate, Paracetamol
Medicine Name Cyclimorph 10 Injection Active Ingredients Cyclizine tartrate, Morphine Tartrate
Medicine Name Cyclimorph 15 Solution for Injection Active Ingredients Cyclizine tartrate, Morphine Tartrate
Medicine Name Detrunorm XL 30 mg modified-release capsules Active Ingredients Propiverine hydrochloride
Medicine Name Eltroxin 100 microgram Tablets Active Ingredients Levothyroxine sodium
Medicine Name Eltroxin 50 microgram Tablets Active Ingredients Levothyroxine sodium
Medicine Name Erythrocin 250mg Tablets Active Ingredients Erythromycin Stearate
Medicine Name Erythrocin 500mg Tablets Active Ingredients Erythromycin Stearate
Medicine Name Erythrocin IV Lactobionate 1.0g Powder for Solution for Infusion Active Ingredients Erythromycin Lactobionate
Medicine Name Erythromycin Tablets BP 250mg. Active Ingredients Erythromycin
Medicine Name Erythroped Adult Tablets Active Ingredients Erythromycin Ethylsuccinate
Medicine Name Erythroped Forte SF 500mg/5ml granules for oral suspension Active Ingredients Erythromycin Ethylsuccinate
Medicine Name Erythroped PI SF 125mg/5ml granules for oral suspension Active Ingredients Erythromycin Ethylsuccinate
Medicine Name Erythroped SF 250mg/5ml granules for oral suspension Active Ingredients Erythromycin Ethylsuccinate
Medicine Name Fucithalmic 10 mg/g Viscous eye drops, suspension Active Ingredients Fusidic Acid Hemihydrate
Medicine Name Genticin 80 mg/2 ml Solution for Injection Active Ingredients Gentamicin sulfate
Medicine Name Genticin Eye/Ear Drops Solution Active Ingredients Gentamicin sulfate
Medicine Name Gentisone HC 0.3% w/v & 1.0% w/v Ear Drops, Suspension Active Ingredients Gentamicin sulfate, Hydrocortisone Acetate
Medicine Name HYTRIN Tablets 10mg Active Ingredients Terazosin monohydrochloride dihydrate
Medicine Name HYTRIN Tablets 2mg Active Ingredients Terazosin monohydrochloride dihydrate
1 - 0 of 44 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 14 March 2017 PIL

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.6 - Special precautions for disposal and other handling

Free text change information supplied by the pharmaceutical company

Update to SmPC section 1, 4.2, 4.3, 4.4, 4.5, 4.8, 5.1, 5.2 and 6.6 and corresponding section of PIL was inline with the SPC

Updated on 14 March 2017 SPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 14 March 2017 SPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.6 - Special precautions for disposal and other handling

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Update to SmPC section 1, 4.2, 4.3, 4.4, 4.5, 4.8, 5.1, 5.2 and 6.6 and corresponding section of PIL was inline with the SPC

Updated on 13 January 2015 PIL

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.2 - Incompatibilities
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

The sections 2, 4.1- 4.6, 4.8, 4.9,  5.1, 5.2, 6.2, 6.6, 7 & 10 of the SmPC were upadted

Updated on 13 January 2015 SPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.2 - Incompatibilities
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The sections 2, 4.1- 4.6, 4.8, 4.9,  5.1, 5.2, 6.2, 6.6, 7 & 10 of the SmPC were upadted

Updated on 6 December 2013 PIL

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

Section 4.8:- Undesirable effects - How to report adverse event
Section 10:- Date of revision of the text is amended

Updated on 6 December 2013 SPC

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.8:- Undesirable effects - How to report adverse event
Section 10:- Date of revision of the text is amended

Updated on 15 May 2013 PIL

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 6.1 - List of excipients
  • Change to section 6.2 - Incompatibilities
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

Section 2.        QUALITATIVE AND QUANTITATIVE COMPOSITION

 

Updated description of composition to read:

Each 2 ml ampoule contains gentamicin sulphate equivalent to 80 mg gentamicin base.

 

Inserted words ‘a full list’ in the sentence to read:

For a full list of excipients, see section 6.1.

 

 

Section 4.1.      Therapeutic indications

 

Removed word ‘injectable’ from this section.

 

 

Section 4.6.      Fertility, pregnancy and lactation

 

Added word ‘fertility’ to title of this section (previously used to read ‘Pregnancy & lactation).

 

 

Section 4.8.      Undesirable effects

 

Inserted the word ‘system’ here to read: Gastro-intestinal system disorders

 

Inserted a hyphen between the words serum and bilirubin to read serum-bilirubin.

 

 

Section 6.1.      List of excipients

 

Added the words ‘for pH adjustment’ after the excipient sulphuric acid.

 

 

Section 6.2.      Incompatibilities

 

Removed word ‘injectable’ from this section

 

 

Section 6.6.      Special precautions for disposal of a used medicinal product or waste materials, derived from such medicinal product and other handling of the product

 

Title of section amended to text above.

Added the phrase ‘For single use only


Section 9.        DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

 

Amended to read:

            Date of first authorisation: 20 April 1995

            Date of last renewal: 20 April 2010

 

 

10.        DATE OF REVISION OF THE TEXT

 

Updated to read:

May 2012

Updated on 15 May 2013 SPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 6.1 - List of excipients
  • Change to section 6.2 - Incompatibilities
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 2.        QUALITATIVE AND QUANTITATIVE COMPOSITION

 

Updated description of composition to read:

Each 2 ml ampoule contains gentamicin sulphate equivalent to 80 mg gentamicin base.

 

Inserted words ‘a full list’ in the sentence to read:

For a full list of excipients, see section 6.1.

 

 

Section 4.1.      Therapeutic indications

 

Removed word ‘injectable’ from this section.

 

 

Section 4.6.      Fertility, pregnancy and lactation

 

Added word ‘fertility’ to title of this section (previously used to read ‘Pregnancy & lactation).

 

 

Section 4.8.      Undesirable effects

 

Inserted the word ‘system’ here to read: Gastro-intestinal system disorders

 

Inserted a hyphen between the words serum and bilirubin to read serum-bilirubin.

 

 

Section 6.1.      List of excipients

 

Added the words ‘for pH adjustment’ after the excipient sulphuric acid.

 

 

Section 6.2.      Incompatibilities

 

Removed word ‘injectable’ from this section

 

 

Section 6.6.      Special precautions for disposal of a used medicinal product or waste materials, derived from such medicinal product and other handling of the product

 

Title of section amended to text above.

Added the phrase ‘For single use only


Section 9.        DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

 

Amended to read:

            Date of first authorisation: 20 April 1995

            Date of last renewal: 20 April 2010

 

 

10.        DATE OF REVISION OF THE TEXT

 

Updated to read:

May 2012

Updated on 27 August 2008 PIL

Reasons for updating

  • New SPC for new product

Updated on 27 August 2008 SPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)